CVD, cardiovascular disease
Pharmaceutics 16 , 571 (2024)
Funding This work was supported by National Natural Science Foundation of China (81771140), Youth Medical Talent Program of Jiangsu Province (QNRC2016068), and Medical Innovation Team of Jiangsu Province (CXTDA2017030)
Pay close attention to: Inclusion and exclusion criteria Location (some trials require in-person visits) Frequency of check ins Study design, like whether the study is randomized and placebo-controlled (a placebo-controlled trial means not everyone receives the medication, which is an important consideration) Study duration (if youre in the placebo group, this is how long without treatment, too!) For instance, some retatrutide clinical trials are only enrolling people with obesity, which means you must be above a certain BMI to qualify
Baseline and interval laboratory monitoring should include: fasting glucose and HbA1c (tirzepatide can cause hypoglycemia in non-diabetic subjects if caloric intake drops too low), lipase and amylase (pancreatitis risk with GLP-1 agonists), liver function tests (AST, ALT, bilirubin), and thyroid panel (TSH, free T3, free T4)
